A Mobile Patient-Facing App for Tracking Patient-Reported Outcomes in Head and Neck Cancer Survivors: Single-Arm Feasibility Study.
ePROs
head and neck cancer
mHealth
mobile phone
Journal
JMIR formative research
ISSN: 2561-326X
Titre abrégé: JMIR Form Res
Pays: Canada
ID NLM: 101726394
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
30
09
2020
accepted:
17
01
2021
revised:
02
12
2020
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Patients with head and neck cancer (HNC) frequently experience disease-related symptoms and treatment adverse effects that impact their overall quality of life. Cancer-specific mobile health apps for patient-related outcomes allow patients to communicate with their clinicians and proactively track their symptoms, which have been shown to improve clinical management and disease outcomes. The purpose of this study was to evaluate the feasibility of LogPAL, a novel iPhone-based mobile health app designed to help HNC survivors track and manage their posttreatment symptoms. Patients who completed curative treatment for HNC in the preceding 24 months were recruited from 2 clinical sites within a single institution. Upon enrollment, participants completed a brief sociodemographic survey, downloaded the app onto their iPhone devices, and were asked to complete a series of biweekly questionnaires (based on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) via the app for an 8-week study period. The primary feasibility endpoints included retention (retaining >80% of the enrolled participants for the duration of the study period), adherence (>50% of the participants completing 100% of the questionnaires over the study period), and usability (a mean system usability scale [SUS] score >68). Additional postintervention questions were collected to assess perceived usefulness, acceptance, and overall satisfaction. Between January and October 2019, 38 participants were enrolled in the study. Three participants dropped out, and 3 were classified as nonusers. The remaining 32 (87%) were eligible for analysis. Their mean age was 57.8 (SD 12.3) years (range 24-77 years, 81% [26/32] male). Overall, 375 of 512 (73.2%) questionnaires were completed, with 17 (53%) of the 32 participants adherent. Participant-reported usability was acceptable; the mean SUS score was 71.9 (95% CI 64.3-79.5) with high satisfaction of LogPAL usefulness and likelihood to recommend to other cancer survivors. This single-arm prospective pilot study showed that LogPAL is a feasible, regularly used, accepted app for HNC survivors, justifying a full-scale pilot. Based on the findings from this study, future iterations will aim to improve usability and test intervention efficacy.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with head and neck cancer (HNC) frequently experience disease-related symptoms and treatment adverse effects that impact their overall quality of life. Cancer-specific mobile health apps for patient-related outcomes allow patients to communicate with their clinicians and proactively track their symptoms, which have been shown to improve clinical management and disease outcomes.
OBJECTIVE
OBJECTIVE
The purpose of this study was to evaluate the feasibility of LogPAL, a novel iPhone-based mobile health app designed to help HNC survivors track and manage their posttreatment symptoms.
METHODS
METHODS
Patients who completed curative treatment for HNC in the preceding 24 months were recruited from 2 clinical sites within a single institution. Upon enrollment, participants completed a brief sociodemographic survey, downloaded the app onto their iPhone devices, and were asked to complete a series of biweekly questionnaires (based on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events) via the app for an 8-week study period. The primary feasibility endpoints included retention (retaining >80% of the enrolled participants for the duration of the study period), adherence (>50% of the participants completing 100% of the questionnaires over the study period), and usability (a mean system usability scale [SUS] score >68). Additional postintervention questions were collected to assess perceived usefulness, acceptance, and overall satisfaction.
RESULTS
RESULTS
Between January and October 2019, 38 participants were enrolled in the study. Three participants dropped out, and 3 were classified as nonusers. The remaining 32 (87%) were eligible for analysis. Their mean age was 57.8 (SD 12.3) years (range 24-77 years, 81% [26/32] male). Overall, 375 of 512 (73.2%) questionnaires were completed, with 17 (53%) of the 32 participants adherent. Participant-reported usability was acceptable; the mean SUS score was 71.9 (95% CI 64.3-79.5) with high satisfaction of LogPAL usefulness and likelihood to recommend to other cancer survivors.
CONCLUSIONS
CONCLUSIONS
This single-arm prospective pilot study showed that LogPAL is a feasible, regularly used, accepted app for HNC survivors, justifying a full-scale pilot. Based on the findings from this study, future iterations will aim to improve usability and test intervention efficacy.
Identifiants
pubmed: 33739291
pii: v5i3e24667
doi: 10.2196/24667
pmc: PMC8075070
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e24667Informations de copyright
©Sewit Teckie, Jeffrey Solomon, Karthik Kadapa, Keisy Sanchez, David Orner, Dennis Kraus, Dev P Kamdar, Lucio Pereira, Douglas Frank, Michael Diefenbach. Originally published in JMIR Formative Research (http://formative.jmir.org), 19.03.2021.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Palliat Med. 2016 Sep;19(9):949-56
pubmed: 27227341
J Natl Compr Canc Netw. 2019 Jan;17(1):57-63
pubmed: 30659130
Stud Health Technol Inform. 2017;245:131-135
pubmed: 29295067
Int J Med Inform. 2019 Sep;129:404-412
pubmed: 31445284
J Med Internet Res. 2018 Nov 16;20(11):e292
pubmed: 30446482
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
J Clin Oncol. 2016 Jan 10;34(2):169-78
pubmed: 26628469
Support Care Cancer. 2017 Mar;25(3):983-999
pubmed: 27900549
Cancer Nurs. 2019 Jan/Feb;42(1):67-78
pubmed: 28945632
Acta Oncol. 2018 Jul;57(7):924-934
pubmed: 29451059
Curr Probl Cardiol. 2019 Aug;44(8):232-266
pubmed: 30185374
Support Care Cancer. 2020 Oct;28(10):4589-4612
pubmed: 32533435
Psychooncology. 2019 Oct;28(10):2060-2067
pubmed: 31379069
J Pediatr Psychol. 2005 Dec;30(8):644-55
pubmed: 16260434
J Med Internet Res. 2019 Dec 20;21(12):e15644
pubmed: 31859682
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683
pubmed: 31189965
JCO Clin Cancer Inform. 2018 Dec;2:1-12
pubmed: 30652585
J Support Oncol. 2011 Jan 1;9(1):e1-e11
pubmed: 21499540
Adv Radiat Oncol. 2016 Feb 18;1(2):115-121
pubmed: 28740878
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Comput Inform Nurs. 2009 May-Jun;27(3):175-83
pubmed: 19411947
JAMA Otolaryngol Head Neck Surg. 2016 Oct 1;142(10):1002-1008
pubmed: 27414519
J Am Med Inform Assoc. 2012 May-Jun;19(3):413-22
pubmed: 21828224
Support Care Cancer. 2020 Mar;28(3):1469-1479
pubmed: 31273501
Acta Oncol. 2013 Feb;52(2):391-9
pubmed: 23244672
JMIR Mhealth Uhealth. 2016 Jun 09;4(2):e29
pubmed: 27282195
Am J Manag Care. 2008 Aug;14(8):530-9
pubmed: 18690769
Ann Palliat Med. 2019 Apr;8(2):104-111
pubmed: 29156896
JAMA Oncol. 2015 Nov;1(8):1051-9
pubmed: 26270597
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Support Care Cancer. 2018 Feb;26(2):361-374
pubmed: 28948360
J Med Internet Res. 2016 Oct 31;18(11):e287
pubmed: 27806926
J Med Internet Res. 2019 Jan 24;21(1):e10875
pubmed: 30679145
Cancer Manag Res. 2017 Aug 18;9:363-371
pubmed: 28860859
Expert Rev Anticancer Ther. 2007 Jul;7(7):1043-53
pubmed: 17627463
JMIR Mhealth Uhealth. 2019 Jan 18;7(1):e11941
pubmed: 30664463
Cancer Nurs. 2013 Jan-Feb;36(1):6-17
pubmed: 22495503
Am Soc Clin Oncol Educ Book. 2016;35:185-98
pubmed: 27249699
Support Care Cancer. 2006 Oct;14(10):1012-9
pubmed: 16538497
J Med Internet Res. 2012 Jan 13;14(1):e6
pubmed: 22246148
J Med Internet Res. 2020 Mar 25;22(3):e12689
pubmed: 32209536
Otolaryngol Head Neck Surg. 2018 Nov;159(5):853-858
pubmed: 29943677